The Truth Emerges On July 29, 2025, Novo issued a press release and held a conference call lowering its sales and profit outlook for 2025, citing "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition." Management also noted that despite the expiry of the FDA grace period for mass compounding on May 22, 2025, company research showed that unsafe and unlawful mass compounding continued
For the study published today in the Annals of Internal Medicine researchers analyzed insurance claims from nearly 3,600 women, ages 16 to 55, comparing pregnancies where GLP-1 medications were continued into the first trimester with pregnancies in which they were stopped
Thats not a question
Fitty GLP-1 Daily helps: Support appetite control
Floyd ND, Kondylis L, Kondylis PD, Reilly JC
The human tri-peptide GHK and tissue remodeling"